About
Our Science
Our Programs
Careers
Investors & Media
Stockholder Tools
Global - Contact
Investor Contact
Kia Khalaghpour, Ph.D.
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1-617-844-6859
kia.khaleghpour@constellationpharma.com
Media Contact
Lauren Arnold
MacDougall Biomedical Communications
+1-781-235-3060
larnold@macbiocom.com
SEC Filings
Filing date | Form | Description | Filing Group | View |
---|---|---|---|---|
4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
View HTML | |
4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
View HTML | |
8-K | Report of unscheduled material events or corporate event |
Current Reports
|
View HTML | |
3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
View HTML | |
4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
View HTML | |
3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
View HTML | |
4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
View HTML | |
4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
View HTML | |
4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
View HTML | |
10-K | Annual report which provides a comprehensive overview of the company for the past year |
Annual Filings
|
EX-101.INS - XBRL INSTANCE DOCUMENT View HTML |
Data provided by Kaleidoscope.
Investors & Media
About
Our Science
Our Programs
Careers
Investors & Media
Stockholder Tools
Investor Contact
Kia Khalaghpour, Ph.D.
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1-617-844-6859
kia.khaleghpour@constellationpharma.com
Media Contact
Lauren Arnold
MacDougall Biomedical Communications
+1-781-235-3060
larnold@macbiocom.com